Literature DB >> 21512052

Pulmonary thermal ablation in patients with prior pneumonectomy.

Constantinos T Sofocleous1, Benjamin May, Elena N Petre, Mithat Gonen, Raymond H Thornton, William Alago, Nabil P Rizk, Damian E Dupuy, Stephen B Solomon.   

Abstract

OBJECTIVE: The purpose of this article is to review the safety and efficacy of thermal ablation of lung malignancies after pneumonectomy.
MATERIALS AND METHODS: We reviewed patients who underwent thermal ablation for malignant lung tumors after pneumonectomy between 1999 and 2009. Patient demographics, complications, procedural success, and oncologic outcomes were recorded. Technique effectiveness was evaluated at imaging 4-6 weeks after ablation. The Kaplan-Meier method was used to evaluate overall survival. A cumulative incidence and competing risk method was used to account for progression-free tumors at the time of patient death.
RESULTS: Of 619 lung ablations, 17 were performed to treat 13 tumors (nine primary and four metastatic) in 12 patients with a single lung. The median tumor size was 2 cm (range, 1.2-4 cm). Technical success was documented in all 17 cases. Technical effectiveness was documented in 10 of 12 patients. Local tumor progression occurred in five lesions within a median of 12 months (range, 10-22 months) after ablation and was treated with repeat ablation in four lesions. Complications included six (35%) of 17 pneumothoraces requiring thoracostomy. Deaths occurred within 2-12 days after three (19%) of 16 ablation sessions. The median time to primary local tumor progression was 18 months (95% CI, 12 months through not reached), and the median time to assisted (after repeat ablation) local tumor progression was 33 months (95% CI, not reached). Median overall survival was 21 months (95% CI, 18-53 months). After excluding the two early deaths complicating the initial ablation procedure, median overall survival was 37 months.
CONCLUSION: Thermal ablation can offer local tumor control after pneumonectomy, despite a relatively high postprocedure clinical risk.

Entities:  

Mesh:

Year:  2011        PMID: 21512052     DOI: 10.2214/AJR.10.5154

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  14 in total

Review 1.  The role of percutaneous image-guided ablation for lung tumors.

Authors:  Elena N Petre; Stephen B Solomon; Constantinos T Sofocleous
Journal:  Radiol Med       Date:  2014-07-01       Impact factor: 3.469

Review 2.  Alternative to surgery in early stage NSCLC-interventional radiologic approaches.

Authors:  Kyungmouk Steve Lee; Bradley B Pua
Journal:  Transl Lung Cancer Res       Date:  2013-10

3.  Microwave Ablation in the Management of Colorectal Cancer Pulmonary Metastases.

Authors:  I Kurilova; A Gonzalez-Aguirre; R G Beets-Tan; J Erinjeri; E N Petre; M Gonen; M Bains; N E Kemeny; S B Solomon; C T Sofocleous
Journal:  Cardiovasc Intervent Radiol       Date:  2018-05-29       Impact factor: 2.740

4.  Stereotactic body radiation therapy for a new lung cancer arising after pneumonectomy: dosimetric evaluation and pulmonary toxicity.

Authors:  Alessandro Testolin; Maria Silvia Favretto; Stefania Cora; Carlo Cavedon
Journal:  Br J Radiol       Date:  2015-08-20       Impact factor: 3.039

5.  Stereotactic body radiotherapy versus percutaneous local tumor ablation for early-stage non-small cell lung cancer.

Authors:  Bryan J Ager; Stacey M Wells; Joshua D Gruhl; Gregory J Stoddard; Randa Tao; Kristine E Kokeny; Ying J Hitchcock
Journal:  Lung Cancer       Date:  2019-09-16       Impact factor: 5.705

6.  Microsimulation model predicts survival benefit of radiofrequency ablation and stereotactic body radiotherapy versus radiotherapy for treating inoperable stage I non-small cell lung cancer.

Authors:  Angela C Tramontano; Lauren E Cipriano; Chung Yin Kong; Jo-Anne O Shepard; Michael Lanuti; G Scott Gazelle; Pamela M McMahon
Journal:  AJR Am J Roentgenol       Date:  2013-05       Impact factor: 3.959

7.  Ki 67 is an independent predictive biomarker of cancer specific and local recurrence-free survival after lung tumor ablation.

Authors:  Constantinos T Sofocleous; Sandeep K Garg; Perry Cohen; Elena N Petre; Mithat Gonen; Joseph P Erinjeri; Robert J Downey; William D Travis; Stephen B Solomon
Journal:  Ann Surg Oncol       Date:  2013-07-30       Impact factor: 4.339

8.  Radiofrequency ablation of T1 lung carcinoma: comparison of outcomes for first primary, metachronous, and synchronous lung tumors.

Authors:  Carole A Ridge; Mikhail Silk; Elena N Petre; Joseph P Erinjeri; William Alago; Robert J Downey; Constantinos T Sofocleous; Raymond H Thornton; Stephen B Solomon
Journal:  J Vasc Interv Radiol       Date:  2014-04-02       Impact factor: 3.682

9.  Computed tomography-guided percutaneous microwave ablation of early stage non-small cell lung cancer in a pneumonectomy patient.

Authors:  Zhigang Wei; Jiao Wang; Xin Ye; Xia Yang; Guanghui Huang
Journal:  Thorac Cancer       Date:  2015-06-15       Impact factor: 3.500

10.  Percutaneous CT-guided microwave ablation as maintenance after first-line treatment for patients with advanced NSCLC.

Authors:  Xiang Ni; Jun-Qing Han; Xin Ye; Zhi-Gang Wei
Journal:  Onco Targets Ther       Date:  2015-11-03       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.